Table 1. Patient characteristics.
| Characteristic | N=108 |
|---|---|
| Age, years (range) | |
| Median | 63 (37-82) |
| ≥ 70 years | 74 (70-82) |
| Gender, n (%) | |
| Male | 69 (64) |
| Female | 39 (36) |
| Diagnosis, n (%) | |
| Chronic lymphocytic leukemia | 98 (91) |
| Small lymphocytic lymphoma | 10 (9) |
| Binet stage, n (%) | |
| A | 19 (18) |
| B | 63 (58) |
| C | 26 (24) |
| Cytogenetic subgroups, n (%) | |
| Trisomy in 12 | 22 (20) |
| Deletion in 11q | 16 (15) |
| Deletion in 13q | 10 (9) |
| Deletion in 17p or TP53 mutation | 8 (7) |
| Complex (≥3 abnormalities) | 5 (5) |
| No abnormalities | 20 (19) |
| Could not be evaluated | 24 (22) |
| IGHV mutational status, n (%) | |
| Mutated | 8 (7) |
| Unmutated | 12 (11) |
| Could not be evaluated | 88 (82) |
| Serum β2microglobulin, n (%) | |
| Normal | 12 (11) |
| Elevated | 7 (7) |
| Could not be evaluated | 89 (82) |
| FCR treatment, n (%) | |
| < 4 cycles | 18 (17) |
| 4 cycles | 28 (26) |
| 6 cycles | 62 (57) |
| Median time from diagnosis, months (range) | 31.5 (0-268) |
FCR=fludarabine, cyclophosphamide and rituximab; IGHV=immunoglobulin heavy-chain variable region gene; n=number.